Loading…
Intensity Therapeutics Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in INTS.
▼ -97.4% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $10.25 | $44.00 | $214.25 | |
| P/B | 8.9x | 2.2x | 9.2x | 8.9x |
| EPS | -$8.56 | -$29.24 | -$34.50 | |
| ROE | -97.73% | -97.73% | -557.51% | -80.06% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RGNTRegentis Biomaterials Ltd | $2.00 | — | 2.2x | — | — | $14.05M |
| HSCSHeartSciences Inc. | $3.03 | — | 42.7x | — | -4239.91% | $13.65M |
| ICUSeaStar Medical Holding Corp | $3.09 | — | 3.1x | — | -356.87% | $13.62M |
| GTBPGT Biopharma, Inc. | $0.30 |
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Company description provided by Yahoo Finance.
| 0.1x |
| 3.8x |
| — |
| -113.52% |
| $13.53M |
| DAREDare Bioscience, Inc. | $0.74 | — | — | — | — | $14.24M |
| CABRCaring Brands, Inc. | $1.39 | — | — | — | -333.74% | $14.41M |